1. Home
  2. ANIX vs CALC Comparison

ANIX vs CALC Comparison

Compare ANIX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.55

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.57

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
CALC
Founded
1982
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
88.3M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ANIX
CALC
Price
$2.55
$0.57
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$8.67
$10.00
AVG Volume (30 Days)
88.7K
427.7K
Earning Date
03-09-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
N/A
EPS
N/A
N/A
Revenue
$210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.33
$0.46
52 Week High
$5.46
$7.20

Technical Indicators

Market Signals
Indicator
ANIX
CALC
Relative Strength Index (RSI) 34.14 32.73
Support Level N/A $0.49
Resistance Level $3.10 $0.79
Average True Range (ATR) 0.20 0.08
MACD -0.02 0.06
Stochastic Oscillator 13.49 9.38

Price Performance

Historical Comparison
ANIX
CALC

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: